First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects

por Wang, Meng-na, Kuang, Yun, Gong, Li-ying, Hua, Ye, Pei, Qi, Guo, Cheng-xian, Cao, Yu, Huang, Jie, Yang, Guo-ping
Publicado 2020